Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Alaa Altahan, Babis Andreadis, Nancy L Bartlett, L Elizabeth Budde, Paolo F Caimi, Sven DeVos, Bhagirathbhai Dholaria, Luis E Fayad, Sameh Gaballa, Thomas M Habermann, Francisco Hernandez-Ilizaliturri, Boyu Hu, Manali Kamdar, Yasmin Karimi, Christopher R Kelsey, Rebecca King, Justin Kline, Susan Krivacic, Ann S LaCasce, Daniel Landsburg, Megan Lim, Marcus Messmer, Priyanka Pophali, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Peter Riedell, Kenneth B Roberts, Aditi Saha, Naoyuki G Saito, Yazeed Sawalha, Stephen D Smith, Lode J Swinnen, Joseph Tuscano, Julie M Vose, Mary Dwyer, Hema Sundar
{"title":"B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.","authors":"Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Alaa Altahan, Babis Andreadis, Nancy L Bartlett, L Elizabeth Budde, Paolo F Caimi, Sven DeVos, Bhagirathbhai Dholaria, Luis E Fayad, Sameh Gaballa, Thomas M Habermann, Francisco Hernandez-Ilizaliturri, Boyu Hu, Manali Kamdar, Yasmin Karimi, Christopher R Kelsey, Rebecca King, Justin Kline, Susan Krivacic, Ann S LaCasce, Daniel Landsburg, Megan Lim, Marcus Messmer, Priyanka Pophali, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Peter Riedell, Kenneth B Roberts, Aditi Saha, Naoyuki G Saito, Yazeed Sawalha, Stephen D Smith, Lode J Swinnen, Joseph Tuscano, Julie M Vose, Mary Dwyer, Hema Sundar","doi":"10.6004/jnccn.2026.0042","DOIUrl":null,"url":null,"abstract":"<p><p>Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncovalent BTK inhibitor) and CAR T-cell therapy (brexucabtagene autoleucel or lisocabtagene maraleucel) have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors. This selection from NCCN Guidelines for B-Cell Lymphomas focuses on the recommendations for the diagnosis and treatment of MCL.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 9","pages":""},"PeriodicalIF":16.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network : JNCCN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jnccn.2026.0042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mantle cell lymphoma (MCL) is a heterogenous subtype of B-cell non-Hodgkin lymphoma (NHL). The treatment landscape of newly diagnosed MCL has evolved in recent years with the incorporation of covalent BTK inhibitors, sensitive assays for the assessment of measurable residual disease (MRD), and predefined maintenance or continuous therapy. Covalent BTK inhibitor-based regimens are also appropriate options for patients with previously untreated classic MCL with TP53 mutations. Pirtobrutinib (a highly selective noncovalent BTK inhibitor) and CAR T-cell therapy (brexucabtagene autoleucel or lisocabtagene maraleucel) have emerged as effective treatment options for refractory or progressive disease after prior treatment with covalent BTK inhibitors. This selection from NCCN Guidelines for B-Cell Lymphomas focuses on the recommendations for the diagnosis and treatment of MCL.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
